Kitov to Host Business Update Call on Monday

to Host Business Update Call on Monday, January 23, 2017

to Discuss Acquisition of Oncology Company, TyrNovo, Ltd.

Development On Track For An NDA Submission to the FDA in Q1 2017

Aviv, Israel -- January 17, 2017 -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical

company, announced that it will host a business update call on Monday, January 23rd at 8:30am Eastern Time to discuss

the recent acquisition of a majority stake in TyrNovo, and to discuss the development plans for KIT-302, which is currently on-track

for an NDA submission during the first quarter of 2017. Kitov previously announced its recent acquisition of a majority stake

in TyrNovo Ltd., a privately held developer of novel small molecules in the -oncology therapeutic field, on January 12, 2017.

Members of management scheduled to speak on the call include Dr. Paul Waymack, MD, Sc.D., Founder, Chairman of the Board and Chief

Medical Officer, Isaac Israel, Chief Executive Officer, Dr. Gil Ben-Menachem, Ph.D. MBA, VP Business Development, and Simcha Rock,

CPA, MBA, Chief Financial Officer.

Kitov Pharmaceuticals

Pharmaceuticals (NASDAQ/TASE: KTOV) is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and

clinical-trial expertise, Kitov's veteran team of healthcare and research professionals maintains a proven track record in streamlined

end-to-end drug development and approval. Kitov's flagship combination drug, KIT-302, intended to treat osteoarthritis pain and

hypertension simultaneously, achieved the primary efficacy endpoint for its Phase III clinical trial. KIT-302's New Drug

Application with the U.S. Food and Drug Administration is currently being prepared for submission. Kitov's newest drug NT219,

a potential immuno-oncology combination product, is being developed by Kitov's recently acquired subsidiary, TyrNovo Ltd. NT219

is a small molecule that presents a new concept in cancer therapy. In combination with various approved oncology drugs, NT219

demonstrated potent anti-tumor effects and increased survival in various cancer models, including sarcoma, melanoma, pancreatic,

lung, ovarian, head & neck, prostate and colon cancers. Its mechanism of action is through the prevention of acquired resistance

in tumors and by regression of resistant tumors. By lowering development risk and cost, including via fast-track regulatory approval

of novel late-stage and other therapeutics, Kitov plans to deliver rapid ROI and long-term potential to investors, while making

a meaningful impact on people's lives. For more information on Kitov, the content of which is not part of this press release,

please visit http://www.kitovpharma.com.

Statements and Kitov's Safe Harbor Statement

statements in this press release are forward-looking statements within the meaning of the safe harbor provisions of the Private

Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements can be identified by

the use of forward-looking words such as "believe", "expect", "intend", "plan", "may",

"should", "could", "might", "seek", "target", "will", "project",

"forecast", "continue" or "anticipate" or their negatives or variations of these words or other

comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue

reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect

our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions,

involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause

our actual results, performance or achievements to be significantly different from any future results, performance or achievements

expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include,

among others, risks relating to: the fact that drug development and commercialization involves a lengthy and expensive process

with uncertain outcomes; our ability to successfully acquire, develop or commercialize our pharmaceutical products; the expense,

length, progress and results of any clinical trials; the lack of sufficient funding to finance the clinical trials; the impact

of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory

approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration

or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and

regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products

once cleared for marketing in a particular market; the introduction of competing products; patents attained by competitors; dependence

on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend

issued patents with protective claims; the commencement of any patent interference or infringement action; our ability to prevail,

obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation,

and/or regulatory actions, and other factors that are discussed in our Registration Statements on Form F-3 filed with the U.S.

Securities and Exchange Commission (the "SEC") (file numbers 333-211477, 333-207117, and 333-215037), in our Annual

Report on Form 20-F for the year ended December 31, 2015 and in our other filings with the SEC, including our cautionary discussion

of risks and uncertainties under "Risk Factors" in our Registration Statements and Annual Reports. These are factors

that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have

listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date which it

is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement, or other information

contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You

are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC's

website, http://www.sec.gov.